摘要
非酒精性脂肪性肝病(NAFLD)被视为代谢综合征(MS)的肝脏表现,除糖脂代谢紊乱外,血清尿酸(SUA)的水平也左右着NAFLD的进展。叙述了两者相关的最新研究成果,指出无论健康个体或患者的SUA都能够独立预测患者MS、2型糖尿病和心血管疾病的风险,其机制可能是SUA通过诱导活性氧(ROS)增加ROS-硫氧还蛋白相互作用蛋白(TXNIP)表达,进而引发pyrin结构域蛋白3炎症小体激活和白细胞介素的分泌;无论基础或临床研究,使用降低SUA的药物可以抑制TXNIP通路,降低血糖水平,减轻肝细胞ROS、炎症、脂肪变性和纤维化。提示减少SUA可能是NAFLD一个有前途的潜在治疗方法,值得基础和临床的进一步研究。
Nonalcoholic fatty liver disease（ NAFLD） is considered the manifestation of metabolic syndrome（ MS） in the liver. Besides glucose and lipid metabolic disorders,the level of serum uric acid（ SUA） is also associated with the progression of NAFLD. This article reviews the research achievements in the association between SUA and NAFLD and points out that SUA can independently predict the risks of MS,type 2 diabetes,and cardiovascular disease in both healthy people and patients. Its mechanism may be that SUA increases the expression of reactive oxygen species（ ROS） / thioredoxin- interacting protein（ TXNIP） through inducing ROS,and then it activates the NLR pyrin domain containing 3 inflammasome and induces the secretion of interleukin. Both basic and clinical research show that the drugs reducing SUA can inhibit the TXNIP pathway,reduce the blood glucose level,and alleviate liver ROS,inflammation,steatosis,and fibrosis. This article suggests that SUA may be a promising therapeutic method for NAFLD and needs further basic and clinical research.
出处
《临床肝胆病杂志》
CAS
2016年第3期437-441,共5页
Journal of Clinical Hepatology
关键词
脂肪肝
尿酸
代谢综合征X
fatty liver
uric acid
metabolic syndrome X
作者简介
徐贝贝（1991-），女，主要从事脂肪性肝病的研究。
通信作者：王炳元，电子信箱：wangby0908@163．com。
